Stoneridge

SRI

Market cap $212M

LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selecti.

Stoneridge, Inc. (SRI) Q1 2026 Earnings Call Transcript

Q1 Performance Demonstrates Solid Progress Continued Strong Momentum with Program Awards for MirrorEye ® and Electronic Controls NOVI, Mich., May 7, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) today announced financial results for the first quarter ended March 31, 2026.

NOVI, Mich., May 4, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) will webcast its first quarter 2026 earnings conference call live on Thursday, May 7, 2026, at 9:00 a.m.

NOVI, Mich., April 28, 2026 /PRNewswire/ -- Driven by accelerating global demand for advanced vision systems, Stoneridge, Inc. (NYSE: SRI) has achieved significant milestones for its award-winning MirrorEye ® Camera Monitor System (CMS), underscoring the company's strong market momentum and continued innovation in commercial vehicle safety and efficiency.

Stoneridge remains a "Buy" despite recent revenue and profit declines, driven by optimism around MirrorEye and long-term growth prospects. Recent results were weak, with 2025 revenue down 6% and net loss widening, but impairment charges and income taxes drove much of the deterioration. MirrorEye revenue grew 69% year-over-year to $111 million, with management projecting significant incremental growth and new business awards totaling $830 million.

Stoneridge, Inc. (SRI) Q4 2025 Earnings Call Transcript

Outperformed End-Markets by 150 Basis Points in 2025 Driven by MirrorEye® Growth of 69% Drove Improvements in Material Cost of 80 bps and Quality-Related Costs of $6.6 Million in 2025 Issues 2026 Midpoint EBITDA Guidance of $22.5 Million and 2027 EBITDA Target of $44 Million 2025 Fourth Quarter Results Sales of $205.2 million Net loss of $(76.9) million ((37.5)% of sales) Includes the after-tax impairment of Control Devices assets of $(16.7) million and income tax expense related to the recording of valuation allowances of $(44.5) million, net Adjusted net loss of $(14.7) million ((7.2)% of sales) Adjusted EBITDA of $3.4 million (1.7% of sales)   2026 Full-Year Guidance Revenue guidance of $625 million - $650 million (midpoint of $638 million) represents growth of 4.2% vs. 2025 sales (excluding Control Devices) of $612 million Guidance conservatively assumes flat end market growth based on current customer expectations (IHS third party production data expects 7.1% year-over-year growth based on our weighted-average OEM end markets) Expecting continued market outperformance led by MirrorEye growth of at least 45% Adjusted EBITDA of $20 million to $25 million (adjusted EBITDA margin of 3.2% to 3.8%) Contribution margin from incremental sales, continued performance improvements and structural cost reductions of $5 million expected to drive significant margin improvement.

NOVI, Mich., March 2, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) will webcast its fourth quarter 2025 earnings conference call live on Thursday, March 12, 2026, at 9:00 a.m.

NOVI, Mich., Feb. 26, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) today announced that it will appoint Aron R.